- By Joe Dangor
Mayo Clinic researchers identify potential new therapy for liver diseases
ROCHESTER, Minn. — Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper's first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. "Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
This research was funded in part by a grant from the National Institutes of Health. The authors report no conflicts of interest.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.
- Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, email@example.com